Rheumatoid Arthritis News

In this video, John M. Davis, III, MD, clinical rheumatologist and professor of medicine at Mayo Clinic College of Medicine and Science, discussed some of the biggest challenges in treating rheumatoid arthritis, including issues with infections and other comorbidities.

In this video, John M. Davis, III, MD, clinical rheumatologist and professor of medicine at Mayo Clinic College of Medicine and Science, discusses some of the latest advancements in the study and treatment of rheumatoid arthritis, including increased understanding of how the gut microbiome impacts the disease.

Katherine Terracina, MD, assistant professor of rheumatology with McGovern Medical School at UTHealth Houston, spoke with Healio about rheumatoid arthritis in young adults and how early detection from a primary care physician is vital for the best possible treatments.

Patients with rheumatoid arthritis who use a digital health application to assess their patient-reported outcomes are more likely to report controlled disease activity, according to data published in JAMA Network Open.

Patients with rheumatoid arthritis who have lower disease activity are more likely to remain in remission after switching from combination therapy to monotherapy, according to data published in The Journal of Rheumatology.

Ozoralizumab demonstrates a long half-life and favorable pharmacokinetics, as well as sustained efficacy, over 52 weeks in patients with rheumatoid arthritis, according to data published in Arthritis Research & Therapy.

Patients with immune checkpoint inhibitor-associated inflammatory arthritis who receive a biologic DMARD demonstrate quicker arthritis control, but also experience faster cancer progression, vs. methotrexate, according to data.

Patients with anxiety or depression are less likely to exhibit healthy self-management for their rheumatoid arthritis, psoriatic arthritis or axial spondyloarthritis, according to data presented at EULAR 2023 Congress.

EULAR has initiated a survey that will collect data directly from patients on the impact and outcomes of rheumatic and musculoskeletal diseases, according to a statement released during the EULAR 2023 Congress.

The longevity of apps and programs aimed at helping patients achieve self-management remains uncertain, according to speakers at a debate session during the EULAR 2023 Congress.